Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Go back to Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
(NASDAQ: TVTX) Delayed: 52.58 +0.28 (0.54%)
Previous Close $52.30    52 Week High $ 
Open $52.88    52 Week Low $ 
Day High $54.83    P/E N/A 
Day Low $52.50    EPS $ 
Volume 2,164,174